Zinc(II)—The Overlooked Éminence Grise of Chloroquine’s Fight against COVID-19?
Aleksandra Hecel, Małgorzata Ostrowska, Kamila Stokowa‐Sołtys, Joanna Wątły, Dorota Dudek, Adriana Miller, Sławomir Potocki, Agnieszka Matera-Witkiewicz, Alicia Domínguez‐Martín, Henryk Kozłowski, Magdalena Rowińska‐Żyrek
Abstract
's RNA-dependent RNA polymerase, and chloroquine and hydroxychloroquine are Zn(II) ionophores-this statement gives a curious mind a lot to think about. We show results of the first clinical trials on chloroquine (CQ) and hydroxychloroquine (HCQ) in the treatment of COVID-19, as well as earlier reports on the anticoronaviral properties of these two compounds and of Zn(II) itself. Other FDA-approved Zn(II) ionophores are given a decent amount of attention and are thought of as possible COVID-19 therapeutics.
Topics & Concepts
HydroxychloroquineChloroquineCoronavirus disease 2019 (COVID-19)MedicinePharmacologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Virology2019-20 coronavirus outbreakInternal medicineImmunologyMalariaOutbreakDiseaseInfectious disease (medical specialty)Vitamin C and Antioxidants ResearchCOVID-19 Clinical Research StudiesAntibiotics Pharmacokinetics and Efficacy